Amgen Inc.
KIF18A INHIBITORS

Last updated:

Abstract:

Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A. ##STR00001##

Status:
Application
Type:

Utility

Filling date:

3 Aug 2020

Issue date:

8 Sep 2022